[HTML][HTML] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

…, ND James, I Turesson, MA Rosenthal… - … England Journal of …, 2004 - Mass Medical Soc
Background Mitoxantrone plus prednisone reduces pain and improves the quality of life in
men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We …

Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study

…, SC Siu, JS Hokanson, C Poile, M Rosenthal… - The Lancet, 2000 - thelancet.com
Background Ventricular arrhythmia and sudden cardiac death late after repair of tetralogy of
Fallot are devastating complications in adult survivors of early surgery, but their prediction …

Glioma

…, SM Pfister, R Nishikawa, M Rosenthal… - Nature reviews Disease …, 2015 - nature.com
Gliomas are primary brain tumours that are thought to derive from neuroglial stem or
progenitor cells. On the basis of their histological appearance, they have been traditionally …

Reference ranges for spirometry across all ages: a new approach

…, AL Coates, H Pan, M Rosenthal… - American journal of …, 2008 - atsjournals.org
Rationale: The Third National Health and Nutrition Examination Survey (NHANES III) reference
is currently recommended for interpreting spirometry results, but it is limited by the lack of …

[HTML][HTML] Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with …

…, R Gattamaneni, L Cher, M Rosenthal… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin
in Glioblastoma Alone and With Lomustine]) was conducted to determine the …

[HTML][HTML] Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer

…, K Fizazi, CM Tangen, M Rosenthal… - Journal of clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Reports have suggested that metastatic site is an important predictor of overall
survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these …

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3 …

…, L Hatteville, D Petrylak, B Tombal, M Rosenthal - The lancet …, 2013 - thelancet.com
Background Docetaxel plus prednisone is standard first-line chemotherapy for men with
metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein …

Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer's disease patients

…, MC Graves, G Bernard, M Rosenthal - Journal of …, 2006 - content.iospress.com
Treatment of Alzheimer’s disease (AD) is difficult due to ignorance of its pathogenesis. AD
patients have defects in phagocytosis of amyloid-β (1-42)(Aβ) in vitro by the innate immune …

Hospitalization and mortality of diabetes in older adults: a 3-year prospective study

MJ Rosenthal, M Fajardo, S Gilmore, JE Morley… - Diabetes …, 1998 - Am Diabetes Assoc
OBJECTIVE In light of increased fatality from acute events and the increased frequency of
chronic complications, life expectancy might well be shortened in older patients with diabetes. …

Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin

…, A Espinosa-Jeffrey, MJ Rosenthal… - Proceedings of the …, 2007 - National Acad Sciences
We have tested a hypothesis that the natural product curcuminoids, which has epidemiologic
and experimental rationale for use in AD, may improve the innate immune system and …